Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field

Peter Valent; Gerald J. Gleich; Andreas Reiter; Florence Roufosse; Peter F. Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M. Leiferman; Michel Arock; Karl Sotlar; Joseph H. Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S. Bochner; Jason Gotlib; Hans Peter Horny; Hans Uwe Simon; Amy D. Klion

doi:10.1586/ehm.11.81

Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field

Peter Valent^*, Gerald J. Gleich, Andreas Reiter, Florence Roufosse, Peter F. Weller, Andrzej Hellmann, Georgia Metzgeroth, Kristin M. Leiferman, Michel Arock, Karl Sotlar, Joseph H. Butterfield, Sabine Cerny-Reiterer, Matthias Mayerhofer, Peter Vandenberghe, Torsten Haferlach, Bruce S. Bochner, Jason Gotlib, Hans Peter Horny, Hans Uwe Simon, Amy D. Klion

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Review article › peer-review

135 Scopus citations

Abstract

Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

Original language	English (US)
Pages (from-to)	157-176
Number of pages	20
Journal	Expert Review of Hematology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1586/ehm.11.81
State	Published - 2012

Funding

P Valent has received a Research Grant from Novartis and a Research Grant from BMS, as well as honoraria from Novartis and BMS. AD Klein is supported by the Intramural Program of the NIAID, NIH. KM Leiferman, HU Simon and GJ Gleich have been supported by grants from GSK. M Arock received honorarium from Novartis. P Vandenberghe is a Senior Clinical Investigator of FWO‑Vlaanderen. T Haferlach is part owner of the Munich Leukemia Laboratory. A Reiter received Honoraria from Novartis and BMS. BS Bochner is a co‑author on existing and pend‑ ing Siglec‑8‑related patents. If Siglec‑8‑related products are developed in the future, BS Bochner may be entitled to a share of royalties received by Johns Hopkins University on the potential sales of such products. The terms of this arrangement are being managed by Johns Hopkins University in accordance with its conflict of interest policies. This study was sup‑ ported by a research grant of the Medical University of Vienna and by the Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Keywords

FIP1L1-PDGFRA
classification
eosinophilic leukemia
hypereosinophilia
hypereosinophilic syndromes
targeted therapy

ASJC Scopus subject areas

Hematology

Access to Document

10.1586/ehm.11.81

Cite this

Valent, P., Gleich, G. J., Reiter, A., Roufosse, F., Weller, P. F., Hellmann, A., Metzgeroth, G., Leiferman, K. M., Arock, M., Sotlar, K., Butterfield, J. H., Cerny-Reiterer, S., Mayerhofer, M., Vandenberghe, P., Haferlach, T., Bochner, B. S., Gotlib, J., Horny, H. P., Simon, H. U., & Klion, A. D. (2012). Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field. Expert Review of Hematology, 5(2), 157-176. https://doi.org/10.1586/ehm.11.81

@article{e0c202a7daf44687935517f849b792de,

title = "Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field",

abstract = "Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.",

keywords = "FIP1L1-PDGFRA, classification, eosinophilic leukemia, hypereosinophilia, hypereosinophilic syndromes, targeted therapy",

author = "Peter Valent and Gleich, {Gerald J.} and Andreas Reiter and Florence Roufosse and Weller, {Peter F.} and Andrzej Hellmann and Georgia Metzgeroth and Leiferman, {Kristin M.} and Michel Arock and Karl Sotlar and Butterfield, {Joseph H.} and Sabine Cerny-Reiterer and Matthias Mayerhofer and Peter Vandenberghe and Torsten Haferlach and Bochner, {Bruce S.} and Jason Gotlib and Horny, {Hans Peter} and Simon, {Hans Uwe} and Klion, {Amy D.}",

note = "Funding Information: P Valent has received a Research Grant from Novartis and a Research Grant from BMS, as well as honoraria from Novartis and BMS. AD Klein is supported by the Intramural Program of the NIAID, NIH. KM Leiferman, HU Simon and GJ Gleich have been supported by grants from GSK. M Arock received honorarium from Novartis. P Vandenberghe is a Senior Clinical Investigator of FWO‑Vlaanderen. T Haferlach is part owner of the Munich Leukemia Laboratory. A Reiter received Honoraria from Novartis and BMS. BS Bochner is a co‑author on existing and pend‑ ing Siglec‑8‑related patents. If Siglec‑8‑related products are developed in the future, BS Bochner may be entitled to a share of royalties received by Johns Hopkins University on the potential sales of such products. The terms of this arrangement are being managed by Johns Hopkins University in accordance with its conflict of interest policies. This study was sup‑ ported by a research grant of the Medical University of Vienna and by the Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",

year = "2012",

doi = "10.1586/ehm.11.81",

language = "English (US)",

volume = "5",

pages = "157--176",

journal = "Expert Review of Hematology",

issn = "1747-4086",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

Valent, P, Gleich, GJ, Reiter, A, Roufosse, F, Weller, PF, Hellmann, A, Metzgeroth, G, Leiferman, KM, Arock, M, Sotlar, K, Butterfield, JH, Cerny-Reiterer, S, Mayerhofer, M, Vandenberghe, P, Haferlach, T, Bochner, BS, Gotlib, J, Horny, HP, Simon, HU & Klion, AD 2012, 'Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field', Expert Review of Hematology, vol. 5, no. 2, pp. 157-176. https://doi.org/10.1586/ehm.11.81

TY - JOUR

T1 - Pathogenesis and classification of eosinophil disorders

T2 - A review of recent developments in the field

AU - Valent, Peter

AU - Gleich, Gerald J.

AU - Reiter, Andreas

AU - Roufosse, Florence

AU - Weller, Peter F.

AU - Hellmann, Andrzej

AU - Metzgeroth, Georgia

AU - Leiferman, Kristin M.

AU - Arock, Michel

AU - Sotlar, Karl

AU - Butterfield, Joseph H.

AU - Cerny-Reiterer, Sabine

AU - Mayerhofer, Matthias

AU - Vandenberghe, Peter

AU - Haferlach, Torsten

AU - Bochner, Bruce S.

AU - Gotlib, Jason

AU - Horny, Hans Peter

AU - Simon, Hans Uwe

AU - Klion, Amy D.

N1 - Funding Information: P Valent has received a Research Grant from Novartis and a Research Grant from BMS, as well as honoraria from Novartis and BMS. AD Klein is supported by the Intramural Program of the NIAID, NIH. KM Leiferman, HU Simon and GJ Gleich have been supported by grants from GSK. M Arock received honorarium from Novartis. P Vandenberghe is a Senior Clinical Investigator of FWO‑Vlaanderen. T Haferlach is part owner of the Munich Leukemia Laboratory. A Reiter received Honoraria from Novartis and BMS. BS Bochner is a co‑author on existing and pend‑ ing Siglec‑8‑related patents. If Siglec‑8‑related products are developed in the future, BS Bochner may be entitled to a share of royalties received by Johns Hopkins University on the potential sales of such products. The terms of this arrangement are being managed by Johns Hopkins University in accordance with its conflict of interest policies. This study was sup‑ ported by a research grant of the Medical University of Vienna and by the Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

PY - 2012

Y1 - 2012

N2 - Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

AB - Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

KW - FIP1L1-PDGFRA

KW - classification

KW - eosinophilic leukemia

KW - hypereosinophilia

KW - hypereosinophilic syndromes

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84863805992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863805992&partnerID=8YFLogxK

U2 - 10.1586/ehm.11.81

DO - 10.1586/ehm.11.81

M3 - Review article

C2 - 22475285

AN - SCOPUS:84863805992

SN - 1747-4086

VL - 5

SP - 157

EP - 176

JO - Expert Review of Hematology

JF - Expert Review of Hematology

IS - 2

ER -

Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this